Overview
- 5 inspections across 5 sites are on record.
- 5 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2025-05-27.
At a glance
Inspections
5
Sites
5
Observations
5
Career since
Feb 2018
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Samsung Biologics Co., Ltd. | 27 May 2025 | Biologics | On file |
| Octapharma AB | 19 Sep 2023 | Biologics | On file |
| GenTrac Inc. | 12 Sep 2019 | Biologics | On file |
| Takeda Austria GmbH | 9 Nov 2018 | Biologics | On file |
| Biogen Inc. | 13 Feb 2018 | Biologics |
Sites inspected
Samsung Biologics Co., Ltd.Yeonsu District, Korea (the Republic of)1 insp.
Octapharma ABStockholm, Sweden1 insp.
GenTrac Inc.Middleton, United States1 insp.
Takeda Austria GmbHLinz, Austria1 insp.
Biogen Inc.Cambridge, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Haarin Chun1 shared
Peng Zhou1 shared
Travis S Bradley1 shared
Olga Simakova1 shared
Alan L Truong1 shared
Scott T Ballard1 shared
Debra M Emerson1 shared
Peter S Kessler1 shared
Li Yun Huang1 shared
Mihaly S Ligmond1 shared
Full investigator report
Get the verbatim findings behind Ze Peng's 5 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site